| A conserved α-helix at the amino terminus of prosomatostatin serves as a sorting signal for the regulated secretory pathway R Mouchantaf, U Kumar, T Sulea, YC Patel Journal of Biological Chemistry 276 (28), 26308-26316, 2001 | 34 | 2001 |
| A different method for steric field evaluation in CoMFA improves model robustness T Sulea, TI Oprea, S Muresan, SL Chan Journal of chemical information and computer sciences 37 (6), 1162-1170, 1997 | 36 | 1997 |
| A glyco-engineering approach for site-specific conjugation to Fab glycans ML Jaramillo, T Sulea, Y Durocher, M Acchione, MJ Schur, A Robotham, ... MAbs 15 (1), 2149057, 2023 | 6 | 2023 |
| A rational engineering strategy for designing protein A-binding camelid single-domain antibodies KA Henry, T Sulea, H van Faassen, G Hussack, EO Purisima, ... PLoS One 11 (9), e0163113, 2016 | 28 | 2016 |
| AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition G Tremblay, M Malouin, S Grothe, A Kalbakji, S Roy, M Pagé, B Paul-Roc, ... Cancer Research 70 (8_Supplement), 1467-1467, 2010 | 2 | 2010 |
| Abstract B024: Single-chain traps targeting transforming growth factor-beta (TGF-beta) home to tumors and reduce tumor growth and metastasis by counteracting TGF-beta-mediated … J Zwaagstra, T Sulea, AEG Lenferink, J Baardsnes, C Collins, C Cantin, ... Cancer Immunology Research 4 (1_Supplement), B024-B024, 2016 | 1 | 2016 |
| Abstract B058: development of AVID200, a novel and highly potent TGF-beta neutralizing immunotherapy MD O'Connor-McCourt, AEG Lenferink, J Zwaagstra, T Sulea, ... Cancer Immunology Research 4 (11_Supplement), B058-B058, 2016 | 1 | 2016 |
| Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM … J Metcalf, A Nielsen, S Prabhu, N Robinson, S Marinacci, N Grinshtein, ... Cancer Research 83 (8_Supplement), LB313-LB313, 2023 | | 2023 |
| Abstract P038: Identification and functional evaluation of monoclonal antibodies specifically targeting human Carbonic Anhydrase IX AEG Lenferink, J Baardsnes, T Sulea, C Wu, M Acchione, ML Jaramillo, ... Cancer Immunology Research 10 (1_Supplement), P038-P038, 2022 | | 2022 |
| Abstract PO-049: Exploiting tumor acidic microenvironment for improved therapeutics NR Larijani, T Sulea, MA Ghahroudi, BP Roc, M Gosselin, J Sheff, ... Cancer Research 80 (21_Supplement), PO-049-PO-049, 2020 | | 2020 |
| An accurate TMT-based approach to quantify and model lysine susceptibility to conjugation via N-hydroxysuccinimide esters in a monoclonal antibody JJ Hill, TL Tremblay, CR Corbeil, EO Purisima, T Sulea Scientific Reports 8 (1), 17680, 2018 | 9 | 2018 |
| An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling SK Kim, L Barron, CS Hinck, EM Petrunak, KE Cano, A Thangirala, B Iskra, ... Journal of Biological Chemistry 292 (17), 7173-7188, 2017 | 40 | 2017 |
| Antagonist of ligands and uses thereof MD O'Connor-McCourt, T Sulea, JC Zwaagstra, J Baardsnes US Patent 8,318,135, 2012 | 26 | 2012 |
| Antagonists of ligands and uses thereof MD O'Connor-McCourt, T Sulea, JC Zwaagstra, J Baardsnes US Patent 8,574,548, 2013 | 2 | 2013 |
| Antagonists of ligands and uses thereof MD O'Connor-McCourt, T Sulea, JC Zwaagstra, J Baardsnes, C Collins US Patent 8,658,135, 2014 | 31 | 2014 |
| Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume GB Tremblay, M Filion, T Sulea | | 2011 |
| Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume GB Tremblay, M Filion, T Sulea US Patent 9,512,211, 2016 | | 2016 |
| Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume GB Tremblay, M Filion, T Sulea US Patent 8,802,826, 2014 | 5 | 2014 |
| Anti-Clusterin Antibodies and Antigen Binding Fragments and their Use to Reduce Tumor Volume GB Tremblay, M Filion, T Sulea US Patent App. 15/359,963, 2017 | | 2017 |
| Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen GB Tremblay, M Filion, T Sulea | | 2019 |
Tudor OpreaCEO, Expert Systems Inc在 expertsystems.inc 的电子邮件经过验证
